A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention

Skip to Content

Clinical Trial Details

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention

Objective

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six months of Anticoagulation Therapy.

IRB Protocol Number
ACCRU SC-1601 (NCT# 03080883)

Clinical Trial Categories

  • Other
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556